gbfi

Results of Multi-laboratory evaluation of Reagena ReaScan TBE IgM rapid test is published in Eurosurveillance

 

The results revealed a high sensitivity of 99.4% when serum samples from 172 previously diagnosed TBE patients from five European countries were analysed.

The mean specificity was 97.6% including two groups of potentially more complicated samples (DENV, JEV, WNV, YFV, ZIKV, CHIKV, A. phagocytophilum, CMV, EBV, HSV and VZV).

In conclusion, study revealed a similarly high sensitivity and high specificity of the ReaScan TBE as compared with the assays used by the diagnostic laboratories.

Other advantages of the assay are:

  • rapid format (20 min)
  • suitability for analysing one sample at each time (i.e. no need to collect samples to have enough numbers to perform an EIA test)
  • the possibility to use it as a Point-of-Care (POC) test to allow rapid diagnosis in primary care settings/outside central laboratories

Please find more information:

Albinsson Bo, Jääskeläinen Anu E., Värv Kairi, Jelovšek Mateja, GeurtsvanKessel Corine, Vene Sirkka, Järhult Josef D., Reusken Chantal, Golovljova Irina, Avšič-Županc Tatjana, Vapalahti Olli, Lundkvist Åke. Multi-laboratory evaluation of ReaScan TBE IgM rapid test, 2016 to 2017. Euro Surveill. 2020;25(12):pii=1900427. https://doi.org/10.2807/1560-7917.ES.2020.25.12.1900427

 tick_banner.jpg